Medical Device News Magazine

NEJM: New Data on COVID-19 Lung Transplants

The New England Journal of Medicine Publishes New National Analysis on COVID-19 Lung Transplantation by Experts in the Smidt Heart Institute at Cedars-Sinai

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • “Our experience treating COVID-19 has shown us that ECMO can be used in carefully selected patients, Joanna Chikwe, MD either as a bridge to lung transplantation, or to allow a patient’s own lungs to heal,” said Joanna Chikwe, MD, founding chair of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai, the Irina and George Schaeffer Distinguished Chair in Cardiac Surgery, and corresponding author of the data published in The New England Journal of Medicine (NEJM).

A Smidt Heart Institute analysis of lung transplantations performed nationally shows significant help for patients with severe, irreversible lung damage from COVID-19.

The analysis of more than 3,000 lung transplants in the U.S. between Aug. 1, 2020, and Sept. 30, 2021, showed that during the pandemic, 7% of the nation’s lung transplants were performed to treat severe, irreversible lung damage caused by COVID-19. More than half of these patients needed ventilators or extracorporeal membrane oxygenation, or ECMO, before their transplant.

joanna chikwe md
Cardiac surgeon Joanna Chikwe, MD, consults with her team. Photo by Cedars-Sinai.

“Our experience treating COVID-19 has shown us that ECMO can be used in carefully selected patients, Joanna Chikwe, MD either as a bridge to lung transplantation, or to allow a patient’s own lungs to heal,” said Joanna Chikwe, MD, founding chair of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai, the Irina and George Schaeffer Distinguished Chair in Cardiac Surgery, and corresponding author of the data published in The New England Journal of Medicine (NEJM). “Most of these COVID-19 patients would have been considered too ill to transplant a few years ago, and the surprising finding of our research was how well they did after lung transplantation.”

While on ECMO, a patient’s blood is pumped out of their body, put through an artificial lung, then pumped back into the patient’s body. The machine-similar to a heart-lung bypass machine-has been around for several decades, although its use for lung failure has increased significantly in the past decade.

In the past, ECMO has been widely considered a “Hail Mary pass” by experts. However, the technology has been employed so often during the global pandemic that Cedars-Sinai physicians have learned new, effective ways to utilize the machine and save lives.

Data published in NEJM was collected from the United Network for Organ Sharing (UNOS), the nonprofit organization that manages the nation’s organ transplant system. Results from 3,039 lung transplantations show:

· The average age of COVID-19 lung transplant patients was 52.

· 21% of COVID-19 lung transplant patients were female.

· 36.6% of COVID-19 lung transplant patients were Hispanic.

· Among the 214 COVID-19 lung transplants, the three-month survival was 95.6%.

· Of the 214 COVID-19 lung transplants, 140 patients had COVID-19 acute respiratory distress syndrome, and 74 patients had COVID-19 pulmonary fibrosis.

“Acute respiratory distress syndrome involves an acute inflammation of the lungs, resulting in decreased ability for the lungs to oxygenate and ventilate,” said Amy Roach, MD, a general surgery resident and Nagel Research Fellow in the Department of Cardiac Surgery in the Smidt Heart Institute and first author of the published data. “In some patients this progresses to COVID-19 pulmonary fibrosis, which causes scarring in the lung and is generally irreversible.”

Throughout the pandemic, Smidt Heart Institute physicians and surgeons have learned how best to treat patients with ECMO.

“Now we know we must mobilize patients and reduce sedatives, whenever possible,” said Dominick Megna, MD, surgical director of the Lung Transplant Program, assistant professor of Cardiac Surgery and an author on the study. “We also have a deeper understanding of how long an individual patient can safely remain on ECMO.”

Between July 2020 and June 30, 2021, Cedars-Sinai provided more than 30,000 hours of ECMO care to patients. Of those 30,000 hours, 21,000 hours were for patients with severe lung disease due to COVID-19.

“Our analysis suggests lung transplants may be a safe option for select patients with the most severe, irreversible lung damage from COVID-19,” said Reinaldo Rampolla, MD, medical director of the Lung Transplant Program at Cedars-Sinai and one of the authors. “However, our hope is that no one has to go through ECMO or lung transplant because of COVID-19. The best protection we have against severe, aggressive disease is vaccination.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.